Gaucher's ERT row heats up as Shire rejects Genzyme suit
This article was originally published in Scrip
Genzyme says it will "aggressively" pursue its complaint that its rival Shire allegedly put out "misleading statements" in a press release about a head to head trial looking at the firms' competing enzyme replacement therapies for Gaucher's disease. Genzyme's comments came after Shire filed for the dismissal of the suit in a Massachusetts court because, as Shire told Scrip, "it was concerned that Genzyme was seeking to stifle both the company's legitimate communications to investors as well genuine discussion and exchange of scientific data."
You may also be interested in...
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.